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Abstract: Capillary electrophoresis (CE) was used to follow Diclofenac tablet dissolution, in very short times and allow-
ing dissolution testing without volume replacement. By using Student´s t test and F-test, this CE method was compared 
with HPLC. Statistical data show that there are no significant differences among them. The drug release kinetic of di-
clofenac tablets was described by various mathematical models and equations. Model-Independent Methods: t50% = 10.34 
min; t80% = 20 min; DE% = 79.41% and MDT = 10.85 min, show that diclofenac tablet dissolution rate is very high, hav-
ing 80% drug dissolution within 20 minutes. Model-Dependent Methods. The kinetics models used were: zero order, first 
order, Hixson–Crowell cube root law, Higuchi model, and Weibull model. Criteria used to choose the best model was by 
comparisson of r
2
 and AIC (Akaike Information Criteria). The model that best adjusts diclofenac tablet dissolution profile 
was the Hixson-Crowell cube root model.  
Keywords: Capillary electrophoresis, diclofenac, dissolution, Hixson-Crowell, quantification, tablets. 
1. INTRODUCTION 
Among Non-Steroidal Anti-Inflammatory Drugs 
(NSAID) Diclofenac sodium 2-[2-[(2,6-dichlorophenyl) 
amino]phenyl]acetate (Fig. 1) can be found. This drug is 
mainly used as an analgesic reducing pain and inflammation, 
in medical conditions such as rheumatoid arthritis, ankylos-
ing spondylitis and osteoarthritis [1]. 
Tablets of 50 mg of diclofenac are produced by the Me-
dicinal Plant of Corrientes (PLAMECOR) under The Minis-
try of Public Health. These are distributed without cost in 
primary care centers across the province.  
USP (United States Pharmacopoeia) recommends di-
clofenac determination by liquid chromatography methods 
[2-4]. Diclofenac determinations by electrochemical tech-
niques are the main research interests: cyclic voltammetry 
[5]; potentiometric sensor [6]; capillary electrophoresis [7-
9]; spectrophotometric methods are also studied [10-12]. 
Other authors focus on diclofenac quantification in vivo us-
ing HPLC-MS [13, 14]. A great deal of research papers are 
focused on official method validation concerning drug re-
lease from dosage forms [15-19].  
In adition, ANMAT (National Drug, Food and Medical 
Technology Administration of Argentina), has not yet estab-
lished analytical methods for diclofenac tablets quality con-
trol [20].
 
Capillary Electrophoresis (CE) is a powerful analytical 
tool that allows separation and analyte quantification in 
much shorter times than HPLC [21, 22], reducing reagent  
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and solvent demand, being more “eco-friendly” than HPLC. 
In addition sample volume requirements are lower than 
HPLC allowing dissolution testing without volume replace-
ment. When a solid dosage form of a drug is administered 
orally, its absorption depends on several processes such as: 
release of the active principle, drug solubilization or dissolu-
tion under physiological conditions, and permeability across 
the gastrointestinal tract. In vivo performance can be pre-
dicted by evaluating in vitro dissolution. The drug release 
kinetic of the diclofenac tablets provided by PLAMECOR 




Fig. (1). Diclofenac sodium chemical structure. 
 
2. MATERIALS AND METHODS 
2.1. Samples and Reagents 
Diclofenac in pure form lot 1004-30-5 (powder), origin 
China, (99.99 % purity, determined by HPLC method) and 
diclofenac 50 mg tablets lot Nº 112/12 from PLAMECOR 
were used. 
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Acetaminophen in pure form lot 4120374 (powder), ori-
gin China, (99.99 % purity, determined by HPLC method) 
from PLAMECOR, was used as internal standard. 
Placebo used in specificity and accuracy determinations, 
was provided by PLAMECOR and its composition is the 
same present in the tablet: magnesium stearate 1%, talc 2%, 
sodium starch glycolate 3.5%, polyvinylpyrrolidone (PVP) 
1.2% and 73.2% green precompact powder. 
All reagents were of analytical grade. Sodium hydroxide, 
sodium borate, sodium phosphate, hydrochloric acid and 
methanol were purchased from Merck (Darmstadt, Ger-
many). Ultra-pure water was obtained from an ultra-pure 
water purification system from Millipore (Bedford, MA, 
USA) and was used in all the CE experiments.  
Stock standard solutions of diclofenac and acetamino-
phen were prepared at a concentration of 2000 ppm by dis-
solving the accurately weighed amount of each drug in wa-
ter. Working standard solutions were prepared by dissolving 
stock standard solutions in water. 
Sample preparation: a stock sample solution was pre-
pared at a concentration of 2000 ppm by dissolving the accu-
rately weighed amount of a pool of 10 diclofenac tablets, in 
water. Working tablet solutions were prepared by dissolving 
the stock sample solution in water. 
Internal standard procedure: an accurate and precise vol-
ume of acetaminophen 70 ppm (internal standard solution) 
was added to diclofenac working standard solution and di-
clofenac sample solution so that they both contain an identi-
cal concentration of internal standard. 
The pHs of the background electrolyte (BGE) solutions 
were adjusted by a pHmeter (HANNA Instrument). All solu-
tions were degassed in an ultrasonic bath Cole Palmer 8891 
(Cole Palmer, Illinois, USA) and filtered through 0.45 m 
nylon membrane (Sartorius, Germany) before use. 
2.2. Instrumentation and Electrophoretic Procedure 
All experiments were carried out on a capillary electro-
phoresis system (Agilent Technologies, Waldbronn, Ger-
many), equipped with a diode array detector. Separation was 
carried out in an uncoated fused-silica capillary of 35.5 cm 
total length (effective length 27 cm), with an inner diameter 
of 75 m (MicroSolv Technology Corporation, Eatontown, 
NJ, USA) in a normal mode, applying a voltage of 20 kV, 
with a typical current of about 85 A. 
The cartridge was maintained at 25.0 C. The wave-
length used for recording the electropherograms was 200 
nm. Injection was made from the positive electrode of the 
capillary hydrodynamically applying 50 mbar of pressure 
for 10 s.  
A careful activation and conditioning of the capillary 
was essential in order to obtain reproducible results and to 
remove substances adsorbed to the capillary wall. Thus, at 
the beginning of every working day the capillary was 
rinsed with: sodium hydroxide 0.1 M (10 min), ultra-pure 
water (10 min) and sodium borate solution 15 mM pH 9.2 
(10 min) which is the BGE. Between runs the capillary was 
successively flushed with sodium hydroxide 0.1 M,  
 
ultra-pure water and BGE for 3 min each. At the end of the 
day the capillary was washed with sodium hydroxide 0.1 M 
(5 min), ultra-pure water (5 min) and then air-dried for 
3min. 
2.3. Method Validation 
For linearity study a calibration curve was constructed 
with diclofenac pure form in a concentration range between 
50 and 90 ppm.  
Specificity was assessed by electrophoretic runs of pla-
cebo prepared with excipients in the same proportion as 
found in 50 mg diclofenac tablets. 
Precision was analyzed as repeatability. A number of 6 
samples were analyzed by triplicate on the same day, by the 
same operator, using the same instrument. ANOVA test was 
performed to analyze the data using Excel
®
 (Microsoft). 
Accuracy was based on the recovery of known amounts 
of analyte in placebo. Spiked samples with different levels of 
diclofenac (80, 100 and 120% tablet concentration), were 
prepared. The analysis was done in triplicate [26]. 
2.4. HPLC –UV Analysis 
HPLC (Agilent 1120 series compact LC) equipped with a 
UV detector was used. 
For diclofenac measurement mobile phase consisting of a 
filtered and degassed mixture of methanol and phosphate 
buffer pH 2.5 (70:30) was used. Diluent was a methanol and 
water mixture (70:30). Column: RP-18C, 125x4.5 mm. Flow 
rate was 1 mL/min. Detection wavelength was set at 276 nm. 
Injection volume was 20 μL. Diclofenac pure form 70 ppm 
solution and Diclofenac tablets solution 81 ppm were used. 
Identity was verified with diclofenac retention time (8.2min). 
Peak areas were determined. Conversion of peak area (A) to 
concentration levels (C) was based on equation 1. 
Csample =  Cdiclo . Adiclo / Asample         (1) 
2.5. Dissolution 
Drug dissolution profile was evaluated employing USP 
basket method, with a Dissolutor AVIC D-II. Dissolution 
testing was carried out under physiological conditions. The 
volume of the dissolution medium was 900 mL. To simulate 
intestinal fluid, a phosphate buffer solution of pH 7.4 was 
employed. Tests were conducted at 37±0.5°C. Mild agitation 
conditions were maintained during dissolution testing. Agita-
tion (or stirring speed) was 50 rpm.  
The selected time points for the dissolution profile were: 
0, 5, 10, 15, 20, 25, 30, 45 and 60 min.  
An aliquot of 500 μL was withdrawn from the dissolutor 
at these time intervals. The sample solution extracted from 
the dissolutor and 17.5 μL acetaminophen (internal standard 
solution) were brought to 2 mL with MilliQ quality water. 
Samples were filtered through 0.45 m nylon membrane 
before use.  
Samples were analyzed using CE. In the data analysis, 
percentage of drug release was calculated using a mean of 
three sample measurements.  
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2.6. Drug Release Kinetics 
2.6.1. Model-Independent Methods  
The model-independent approaches performed to char-
acterize drug release were: tx%, time necessary to release a 
determined percentage of drug (t50% and t80%); Dissolution 
efficiency (DE), based on equation 2, area under the disso-
lution curve up to a certain time, t, expressed as a percent-
age of the area of the rectangle described by 100% dissolu-
tion in the same time; and Mean Dissolution Time (MDT), 
equation 3. 
DE (%) = 100.ABC 
T
0 / Q100.T        (2) 
MDT =  [ti. Qi] / Q

          (3) 
2.6.2. Model-Dependent Methods 
The kinetics models used were: zero order, as cumulative 
amount of drug release vs.time; first order as ln cumulative 
percentage of drug remaining vs. time; Hixson–Crowell cube 
root law, as cube root percent drug remaining vs. time; Hi-
guchi model, as cumulative percentage of drug release vs. 
square root of time; and Weibull model, as ln dissolved 
amount of drug vs. ln of time (Table 1). 
3. RESULTS AND DISCUSSION 
Electropherogram of diclofenac pure form (Fig. 2). 
3.1. Method Validation 
Calibration Curve: plotting area ratio (diclofenac/ aceta-
minophen) vs. Diclofenac concentration, a good linearity has 
been found from the regression analysis [y = (0.0208 ± 
0.0007)x – (0.0292 ± 0.0479)] with r
2
 = 0.9972 with a 95% 
confidence level. Linear range of the essay was 50-90 ppm 
(Fig 3).  
Electrophoretic analysis of placebo demonstrates the 
chemical inertia of diclofenac tablets excipients, and there-
fore method specificity (Fig. 4). 
The proposed method was found to be highly precise, 
having a Relative Standard Deviation for repeatability 
(n=10) of 1.72%, below the maximum amount accepted by 
the pharmacopoeias for pharmaceutical preparations 
(SD% 2%). 
Accuracy: recovery of analyte in placebo 100.36 – 
103.47%, values that fall within the requirements set by USP 
and ANMAT. (Table 2). 
This CE method was compared with HPLC [26]. 
ANOVA test was performed to analyze the data Results are 
shown in Table 3. Statistical data obtained by using Stu-
dent’s t-test and F-tests show no significant difference be-
tween the methods (p>0.05). A confidence level of 95% was 
considered.  
 
Table 1. Model-dependent methods. 
Zero order Q1 = Q0 + K0.t 
First order ln Q1 = ln Q0 + K1.t 
Hixson-Crowell Q0 
1/3 – Q1 
1/3 = K1.t 
Higuchi Q1 = KH.t 
1/2 




-Q)]} = .ln(t-t0) – .ln td 


Fig. (2). Diclofenac pure form electropherogram. Voltage of 20 kV, 
current 85 A. Electropherograms were recorded at 200 nm. Injec-
tion was made hydrodynamically applying 50 mbar of pressure for 
10 s. BGE: sodium borate solution 15 mM pH 9.2. 

Fig. (3). Calibration curve, (diclofenac/acetaminophen area) vs. 
Diclofenac concentration (ppm).  
 

Fig. (4). Placebo electropherogram. 
 
 Calibration curve
 Diclofenac concentration (ppm)  
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3.2. Dissolution Profile 
 
Fig. (5). Diclofenac dissolution profile. 
 
3.3 Drug Release Kinetics 
3.3.1. Model-Independent Methods  
Calculated parameters: 
t50% = 10.34 min 
t80% = 20 min 
DE% = 79.41% 
MDT = 10.85 min 
These results show that Diclofenac tablet dissolution 
rate is very high, having 80% drug dissolution within 20 
minutes.  
3.3.2. Model-Dependent Methods 
Fig. (6). shows the results of the kinetic models used. 
The criteria used to choose the best model was by com-
parisson of r
2
 and AIC (Akaike Information Criteria). The 
highest adjusted r
2
 and the lowest AIC determine the model 
that best adjusts diclofenac dissolution profile. (Table 4). 
Based on these two criteria, the model that best adjusts 
diclofenac dissolution profile was the Hixson-Crowell cube 
root model, in wich the surface area of the tablet exposed to 
the dissolution medium, varies throughout the process as a 
function of the cubic root of the squared volume of the 
solid. 
CONCLUSION 
The CE method has been confirmed to be useful for the 
quality control of diclofenac 50 mg tablets, without interfer-
ence from common excipients. This method was found to be 
simple, rapid and specific, allowing separation and analyte 
quantification in much shorter times, reducing reagent and 
solvent demand, being more “eco friendly” than HPLC. In 
addition sample volume requirements in CE are lower than 
Table 2. Accuracy (recovery of analyte in placebo). 












Table 3. Statistical comparison of the CE method with the reference method. 
Parameter CE Method HPLC-UV Method 
Xm ± SD 48.1 ± 0.8 49.5 ± 0.7 
RSD% 1.73 1.38 
S2 0.69 0.47 
F  1.4672 (3.1788) 
t  -4.2247 (2.1009) 
(Values in parentheses correspond to critical values tabulated for p = 0.05). 
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HPLC allowing dissolution testing without volume replace-
ment. Diclofenac dissolution profile adjusts best to the Hix-
son-Crowell cube root model. Diclofenac tablet dissolution 
rate is very high, having 80% drug dissolution within 20 
minutes. 
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Fig. (6). Model-Dependent Methods. 
 
Table 4. Comparisson of r
2




Zero order 0,9782 15,2552 
First order 0,9837 -12,1213 
Hixson-Crowell  0,9984 -27,8613 
Higuchi  0,9979 3,4225 
Weibull  0,9634 -6,6849 
 
Fast and Efficient Monitoring of Diclofenac Dissolution Profile by CE Current Pharmaceutical Analysis, 2014, Vol. 10, No. 1     43 
REFERENCES 
[1] Lorenzo, P.; Moreno, A.; Leza, J.C.; Lizasoain, I.; Moro, M.A. 
Farmacología Básica y Clínica, 17 ed; Médica Panamericana: 
Spain, 2005. 
[2] United States Pharmacopeia XXIV, National Formulary XX US 
Pharmacopeial Convention, Rockville, Maryland, 2002. 
[3] Arcelloni, C.; Lanzi, R.; Pedercini, S.; Molteni, G.; Fermo, I.; Pon-
tirolic, A. High-performance liquid chromatographic determination 
of diclofenac in human plasma after solid-phase extraction. J. 
Chromatogr. B., 2001, 763(1), 195–200. 
[4] Kuhlmann, O.; Stoldt, G.; Struck, H.G.; Krauss, G.J. Simultaneous 
determination of diclofenac and oxybuprocaine in human aqueous 
humor with HPLC and electrochemical detection. J. Pharmaceut. 
Biomed., 1998, 17(8), 1351–1356.  
[5] Blanco-Lopez, M.C.; Fernandez-Llano, L.; Lobo-Castanon, M.J. 
Potentiometric immunosensor using artificial antibody based on 
molecularly imprinted polymers. Anal. Lett., 2004, 37(5), 915-927.  
[6] Mojtaba, S.; Fíame, J.; Sohrab, E. Preparation of a diclofenac po-
tentiometric sensor and its application to pharmaceutical analysis 
and to drug recovery from biological fluids. J. Pharmaceut. Bio-
med., 2005, 37(5), 943–947. 
[7] Solangi, A.R.; Memon, S.Q.; Mallah, A.; Khuhawar, M.Y.; 
Bhanger, M.I. Development and implication of a capillary electro-
phoresis methodology for ciprofloxacin, paracetamol and di-
clofenac sodium in pharmaceutical formulations and simultane-
ously in human urine samples. Biomed Chromatogr., 2009, 23(9), 
1007-1013.  
[8] Macia, A; Borrull, F; Calull, M; Aguilar, C. Capillary electrophore-
sis for the analysis of non-steroidal anti-inflammatory drugs. 
Trends in Anal. Chem., 2007, 26(2), 133-153. 
[9] Aurora-Prado, M.S; Steppe, M; Tavares, M; Kedor-Hackmann, E; 
Santoro, M. Comparison Between Capillary Electrophoresis and 
Liquid Chromatography for the Determination of Diclofenac So-
dium in a Pharmaceutical Tablet. J. AOAC. Int., 2002, 85(2), 333-
340 
[10] Agatonovi-Ku	trin, S.; 
ivanovi, L.; Zeevi, M.; Radulovi, D. 
Spectrophotometric study of diclofenac-Fe(III) complex. J. Phar-
maceut. Biomed., 1997, 16(1), 147-153. 
[11] De Souza, R.; Tubino, M. Spectrophotometric determination of 
diclofenac in pharmaceutical preparations. J. Braz. Chem. 
Soc., 2005, 16(5), 1068-1073. 
[12] Monzón, C.; Sarno, M.C.; Delfino, M. Diclofenac quantification: 
analytical attributes of a spectrophotometric method. Lat. Am. J. 
Pharm., 2011, 30(5), 1001-1004.  
[13] Mayer, B.X.; Namiranian, K.; Dehghanyar, P.; Stroh, R.; Mascher, 
H.; Müller, M. Comparison of UV and tandem mass spectrometric 
detection for the high-performance liquid chromatographic deter-
mination of diclofenac in microdialysis samples. J. Pharmaceut. 
Biomed., 2003, 33(4), 745-754.  
[14] Ma, S.; Zhu, M.M. Recent advances in applications of liquid chro-
matography–tandem mass spectrometry to the analysis of reactive 
drug metabolites. Chem. Biol. Interact., 2009, 179(1), 25-37.  
[15] Sánchez, V.; Carreño, P.; Castelletto, M. Liberación y permeación 
de diclofenaco sódico desde matrices hidrofílicas. Acta. Farm. 
Bonaerense., 2001, 20(2), 101- 104. 
[16] Rezende Schaffazick, S.; Raffin Pohlmann, A.; De Lucca Freitas, 
L.; Stanisçuaski Guterres, S. Caracterização e estudo de estabilida-
de de suspensões de nanocápsulas e de nanoesferas poliméricas 
contendo diclofenaco. Acta. Farm. Bonaerense., 2002, 21(2), 99-
106. 
[17] Baccarin, M.; Evangelista, R.; Lucinda-Silva, R. Ethylcelullose 
microspheres containing sodium diclofenac: development and 
characterization. Acta. Farm. Bonaerense., 2006, 25(2), 401- 404. 
[18] Dos Santos, L.; Guterres, S.; Bergold, A. Caracterização e qualifi-
cação de diclofenaco de sódio como padrão secundário, Lat. Am. J. 
Pharm., 2007, 26(3), 355-361.  
[19] Olivera, M.; Allemandi, D.; Manzo, R. Equivalencia farmacéutica 
en comprimidos recubiertos de diclofenac sódico, Acta Farm. Bo-
naerense. 2003, 22(2), 143-146. 
[20] Farmacopea Nacional Argentina. 8va edición. ANMAT. 2011. 
[21] Harris, D. C, Análisis químico cuantitativo, 3rd ed; Reverté: Barce-
lona, 2007. 
[22] Lachmann, B., M. Kratzel, Noe, C.R. Rapid determination of di-
clofenac in pharmaceutical formulations by capillary zone electro-
phoresis. Sci. Pharm., 2012, 80(2), 311-316. 
[23] Aguilar Ros, A; Caamaño Somoza, M; Martin-Martin, F.R; Mon-
tejo Rubio, M.C. Biofarmacia y Farmacocinética., 1ra. ed; El-
sevier: Barcelona, 2008.  
[24] Ostrowski, M.; Baczek, T. The Progress on the In Vivo-In Vi-
tro Correlation (IVIVC) for Immediate Release Dosage Form as an 
Alternative to Bioavailability Studies. Curr. Pharm. Anal., 2010, 
6(4), 289-298. 
[25] Kumar, N.; Sangeetha, D.; Reddy, P.S.; Reddy A.M. Development 
and Validation of a Dissolution Test for Delayed Release Capsule 
Formulation of Duloxetine Hydrochloride. Curr. Pharm. Anal., 
2012, 8(3), 236-246. 
[26] Miller, J.C.; Miller, J.N. Estadística y Quimiometría para Química 
Analítica, 1ra. ed; Pearson-Prentice Hall: Madrid, 2000.  
 
Received: April 10, 2013 Revised: June 26, 2013    Accepted: June 28, 2013 
 
 
